Beta-blockers in cirrhosis and refractory ascites: A retrospective cohort study and review of the literature

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 2, 2015, Pages 129-137

  Kimer, Nina ^a   Feineis, Martin ^a   Møller, Søren ^a   Bendtsen, Flemming ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Beta blockers; Cirrhosis; Portal hypertension; Refractory ascites; Survival

Indexed keywords

ALBUMIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; DIURETIC AGENT; METOPROLOL SUCCINATE; PROPRANOLOL;

ASCITES; BACTERIAL PERITONITIS; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DIURETIC THERAPY; DRUG INDICATION; DRUG USE; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY ASCITES; RETROSPECTIVE STUDY; REVIEW; SCLEROTHERAPY; SEPSIS; STOMACH DISEASE; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; AGED; CASE CONTROL STUDY; COMPLICATION; ESOPHAGEAL AND GASTRIC VARICES; HYPERTENSION, PORTAL; MIDDLE AGED;

ADRENERGIC BETA-ANTAGONISTS; AGED; ASCITES; CASE-CONTROL STUDIES; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROPRANOLOL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84921365484     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.948053     Document Type: Review

References (46)

1. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-54.
2. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, Uriz J, Quinto L, Ventura PJ, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34: 46-52.
3. de Franchis R, Baveno VF. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010;53:762-8.
4. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417.
5. Moller S, Henriksen JH, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int 2008;2:416-28.
6. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006;55:vi1-12.
7. Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010;51:1675-82.
8. Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-10.
9. Gines P, Guevara M, De Las Heras D, Arroyo V. Review article: albumin for circulatory support in patients with cirrhosis. Aliment Pharmacol Ther 2002;16:24-31.
10. Giannelli V, Lattanzi B, Thalheimer U, Merli M. Beta-blockers in liver cirrhosis. Ann Gastroenterol 2014;27:20-6.
11. Mastai R, Bosch J, Navasa M, Kravetz D, Bruix J, Viola C, et al. Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis. J Hepatol 1987;4:71-9.
12. Ohnishi K, Nakayama T, Saito M, Hatano H, Tsukamoto T, Terabayashi H, et al. Effects of propranolol on portal hemodynamics in patients with chronic liver disease. Am J Gastroenterol 1985;80:132-5.
13. Sersté T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010;52:1017-22.
14. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997;25:63-70.
15. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254-61.
16. Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco- Italian Multicenter Study Group. N Engl J Med 1991;324:1532-8.
17. Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol 2014;60:643-53.
18. Rockey DC. Pharmacologic therapy for gastrointestinal bleeding due to portal hypertension and esophageal varices. Curr Gastroenterol Rep 2006;8:7-13.
19. Tripathi D, Hayes PC. Beta-blockers in portal hypertension: new developments and controversies. Liver Int 2014;34:655-67.
20. Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of a multicenter randomized trial. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. J Hepatol 1989;9: 75-83.
21. Garcia-Pagan JC, Morillas R, Banares R, Albillos A, Villanueva C, Vila C, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology 2003;37:1260-6.
22. Gatta A, Merkel C, Sacerdoti D, Bolognesi M, Caregaro L, Zuin R, et al. Nadolol for prevention of variceal rebleeding in cirrhosis: a controlled clinical trial. Digestion 1987;37:22-8.
23. Lebrec D, Poynard T, Bernuau J, Bercoff E, Nouel O, Capron JP, et al. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology 1984;4:355-8.
24. Pascal JP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987;317:856-61.
25. Sersté T, Francoz C, Durand F, Rautou PE, Melot C, Valla D, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol 2011;55:794-9.
26. Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell'Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol 2006;101:506-12.
27. Villanueva C, Lopez-Balaguer JM, Aracil C, Kolle L, Gonzalez B, Minana J, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol 2004;40:757-65.
28. Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: a randomized multicenter trial. The PROVA Study Group. Hepatology 1991;14:1016-24.
29. Ink O, Servent L, Attali P, Pelletier G, Buffet C, Etienne JP. [Propranolol prevention of hemorrhagic recurrence caused by rupture of esophageal varices: worsened prognosis in ascites and jaundice]. Gastroenterol Clin Biol 1985;9:819-23.
30. Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014;146:1680-90.
31. Galbois A, Das V, Thabut D, Maury E, Ait-Oufella H, Housset C, et al. Beta-blockers have no effect on outcomes in patients with cirrhosis and severe infections. Hepatology 2011;53:1412-13.
32. Robins A, Bowden A, Watson W, Smith F, Gelson W, Griffiths W. Beta-blockers in cirrhosis patients with refractory ascites. Hepatology 2014;59:2054-5.
33. Agustin A, Javier Z. Beta-blockers in patients with cirrhosis and refractory ascites. Hepatology 2011;53:1783.
34. Angeli P. Beta-blockers and refractory ascites in cirrhosis: the message of a team of true scientists. J Hepatol 2011;55:743-4.
35. Garcia-Pagan JC. Portal hypertension: nonselective betablockers in patients with refractory ascites. Nat Rev Gastroenterol Hepatol 2011;8:10-11.
36. Krag A, Bendtsen F, Moller S. Does cardiac dysfunction explain deleterious effects of beta-blockers in cirrhosis and refractory ascites? Hepatology 2011;53:370-1.
37. Krag A, Moller S, Burroughs AK, Bendtsen F. Betablockers induce cardiac chronotropic incompetence. J Hepatol 2012;56:298-9.
38. Kurt M. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2011;53:1411-12.
39. Lo GH. Effects of beta-blockers on survival for patients with cirrhosis and refractory ascites. Hepatology 2011;53:1068-9.
40. Thevenot T, Cervoni JP, Monnet E, Sheppard F, Martino VD. Is this really the end of beta-blockers in patients with cirrhosis and refractory ascites? Hepatology 2011;53:715-16.
41. Wong F, Salerno F. Beta-blockers in cirrhosis: friend and foe? Hepatology 2010;52:811-13.
42. Ideo G, Bellati G, Fesce E, Grimoldi D. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study. Hepatology 1988;8:6-9.
43. Lebrec D, Poynard T, Capron JP, Hillon P, Geoffroy P, Roulot D, et al. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial. J Hepatol 1988;7:118-25.
44. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258-66.
45. Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010;59:105-10.
46. Krag A, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut 2012;61:967-9.